PDC Therapeutics announces that the phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme

The phase 1 study of RS-0139 is now part of the ESMO Congress 2026 scientific programme, to be held in Madrid at 23-27 October 2026:

“First-in-human phase Ia/Ib study of RS-0139, an integrin-targeted docetaxel prodrug, in advanced solid tumors”

 

Further information will be available after the ESMO Congress 2026.